top of page
Search
Cracking the Code: New ISAR Study Reveals How T2- and Non-T2 Inflammatory Pathways Predict Severe Asthma Exacerbations
A novel Bayesian Network analysis on the International Severe Asthma Registry (ISAR) has identified key clinical and biological pathways...
Jul 142 min read
Severe asthma biologic access criteria should consider long-term oral corticosteroid (LTOCS) users with low blood eosinophil counts (BEC): Implications of STAR study
The real-world study, “ Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in...
Jun 123 min read
Minimizing Steroid Burden in Severe Asthma: Real-World Data Demonstrate Biologics as a Game Changer
Drawing on data from over 5,600 severe asthma patients across real-world specialist and primary care settings in 22 countries, the SOLAR...
Jun 43 min read
New update from the International Severe Asthma Registry (ISAR)!
New real-world insights from the International Severe Asthma Registry (ISAR), spanning data from over 25 countries, have been featured in...
May 211 min read
Biologics for asthma prevent new-onset diabetes, major adverse cardiovascular events (MACE) as well as other oral corticosteroid (OCS)-related adverse events: Ground-breaking results from SOLAR II
The real-world SOLAR II study shows that biologic initiators had 18% lower risk of developing any oral corticosteroid (OCS)-related...
May 193 min read
Switching or stopping biologic therapy was associated with worse clinical outcomes than continuing the initial therapy: Results from CLEAR
A recently published study in Pragmatic and Observational Research, “Real-world biologic use patterns in severe asthma, 2015–2021: the...
Mar 183 min read
bottom of page